对6岁或以下儿童肿瘤切除后采用带血管腓骨与异体骨近端股骨重建是否成功?
本研究回顾两个肉瘤中心1997至2010年间6例6岁或以下因骨肉瘤行近端股骨切除、采用保留近端骨骺的带血管腓骨自体骨联合大块异体骨重建的患儿,中位随访17年。6例均获异体骨愈合,但5例再手术、4例最终移除移植物,仅1例原重建维持至27年,MSTS评分在未翻修时为38%,移除重建改其他方法后为88%。作者因重建物存活差、并发症多且结果不可预测而停用该技术,改用假体置换。
要点
- 6例中6例异体骨愈合,5例再手术,4例最终移除移植物。
- 仅1例原重建维持27年,术前MSTS评分中位38%,改其他重建后中位88%。
- 作者因重建物存活差、并发症多且结果不可预测而停用该技术,改用假体置换。
核心结论
- 作者认为,对近端股骨肉瘤幼儿采用带血管腓骨与异体骨的生物学重建对多数患者不是持久解决方案,导致频繁非计划再手术和翻修;仅6例中1例重建维持至成年;因重建物存活差、并发症频繁且结果不可预测,作者已停用该技术,改用假体置换。
研究设计与样本
- 回顾性分析两个肉瘤中心1997年至2010年间收治的6例6岁或以下近端股骨骨肉瘤患儿,均行保留近端骨骺的带血管腓骨自体骨联合大块异体骨重建,近端股骨切除长度中位13 cm(范围11至14 cm),中位随访17年(范围14至27年),证据等级为Level IV治疗性研究。
主要发现
- 6例中6例获得异体骨愈合,愈合距指数手术中位8个月。
- 6例中5例再手术,4例在术后中位19个月(范围7至40个月)的翻修手术中移除移植物。
- 仅1例在27年后仍维持原重建,尽管术后56个月发生骨骺滑脱并手术矫正。
- 6例中2例在取材部位发生腓总神经麻痹;所有患者均残留1至7 cm肢体不等长。
- 任何翻修前MSTS评分中位38%(范围33%至93%);4例移除生物学重建并采用其他方法重建者,最近随访MSTS功能评分中位88%(范围73%至93%)。
关键数值与推荐
- 当髋臼直径<36 mm时,一般行带血管腓骨自体骨联合大块异体骨重建。
- 异体骨愈合中位时间8个月;翻修或移除移植物中位时间19个月(范围7至40个月)。
- 任何翻修前MSTS评分中位38%(范围33%至93%);改其他重建后MSTS评分中位88%(范围73%至93%)。
临床怎么用
- 作者因重建物存活差、并发症频繁且结果不可预测,已停用带血管腓骨与异体骨的生物学重建,改用假体置换。
- 原文未据此给出其他推荐。
局限性
- 本研究为小样本系列,仅6例患者。
- 2例随访20年和27年的患者最近5年未随访,无法确定其当前状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treating bone sarcomas in young children, particularly in the proximal femur, is challenging because of the need to preserve growth potential, maintain joint function, and conserve bone for future revisions. In 1997, we introduced a new technique combining a vascularized fibula that preserved the proximal epiphysis to substitute for the femoral head and physis with a massive bone allograft aimed at providing a supportive scaffold for the autograft during growth. This approach initially showed promising results in both anatomic and functional restoration, but because it was a complex operation, we believed that longer term follow-up of this procedure would be helpful to judge its value as a potential reconstructive option. QUESTIONS/PURPOSES: (1) What proportion of patients achieved allograft union; what proportion exhibited radiologic signs of vitality in the vascularized fibula, demonstrating bone growth and remodeling; what proportion avoided revision surgery; and what complications were observed with this technique? (2) What were the observed outcome scores using the Musculoskeletal Tumor Society (MSTS) score? (3) What was the status of the hip after treatment? METHODS: Between 1997 and 2010, a total of 14 patients who were 6 years old or younger underwent resection of the proximal femur for a bone sarcoma in two sarcoma centers. Six patients were treated with a vascularized fibular autograft plus bulk allograft reconstruction. The median (range) length of the proximal femur resection was 13 (11 to 14) cm. During the period in question, we generally performed the vascularized fibular autograft plus bulk allograft when the acetabular diameter was < 36 mm. None of those who had the fibula autograft plus bulk allograft reconstruction were lost to follow-up before 2 years without meeting a study endpoint (revision, reoperation) or died prior to 2 years with implants intact. All six patients in the original group had either a follow-up of at least 14 years or had met a study endpoint (revision, reoperation) before that minimum surveillance duration; these patients were the focus of the current study. We noted that two patients had follow-up periods of 20 and 27 years but have not been seen in the last 5 years; they were included for survivorship analysis purposes, yet we emphasize that we cannot ascertain their current status. The median (range) follow-up was 17 (14 to 27) years. RESULTS: Six of six patients achieved allograft union, while five of six underwent reoperations, and four of six had the graft removed as part of a revision procedure at a median (range) of 19 (7 to 40) months. Only one patient maintained the original reconstruction after 27 years, despite an epiphysiolysis that occurred 56 months after surgery, which was corrected surgically. The other five patients experienced a complication of the reconstruction at a median (range) onset at 19 (7 to 40) months after surgery. Two of the six patients had a common peroneal nerve palsy at the harvested site. Allograft union was observed a median of 8 months from the index procedure. All patients presented residual limb length discrepancy ranging from 1 to 7 cm. The median (range) MSTS score before any revision was 38% (33% to 93%). Four of the six patients underwent removal of the biological reconstruction and were reconstructed by other methods. They displayed a median (range) MSTS functional score of 88% (73% to 93%) at most recent follow-up. One of the six patients showed progressive diaphyseal hypertrophy, growth, and remodeling of the epiphysis, along with integration with the allograft, and had a final limb length discrepancy of -1 cm. The vascularized fibular epiphysis was enlarged and remodeled to provide a new femoral head and grew similar to the physis of the native femoral head in this one patient. CONCLUSION: Biological reconstruction using a vascularized fibula and bone allograft in young patients with proximal femur sarcoma was not a durable solution for most patients, and it resulted in frequent unplanned reoperations and revisions. Only one of six patients in this small series had a reconstruction that lasted into adulthood. Even though this was a small group of patients, the poor survival of the construct, the frequent complications, and the unpredictable results associated with it led us to discontinue its use in favor of prosthetic replacement. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- Cevolani L, Staals EL, Fernández-Fernández T, et al. Is Proximal Femur Reconstruction With a Vascularized Fibula and Allograft Successful at Reconstructing a Tumor Resection in Children 6 Years of Age or Younger? Clin Orthop Relat Res. 2025. PMID: 39964135. doi:10.1097/CORR.0000000000003414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。